Company: AGIO
Filing Date: 2025-06-18
Form Type: S-8
Source: 0001193125-25-142763
Chunk: 0

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-06-18
Form: S-8
Chunk 0
---
As filed with the Securities and Exchange Commission on June 18, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter)

| Delaware                                 |     |         26-0662915 |
| (State or Other Jurisdiction of          
 Incorporation or Organization)           |     |   -I.R.S. Employer 
 Identification No. |
| 88 Sidney Street                         
 Cambridge, MA                            |     |              02139 |
| (Address of Principal Executive Offices) |     |          -Zip Code |

2023 Stock Incentive Plan, as amended (Full Title of the Plan) Brian Goff Chief Executive Officer Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge, MA 02139 (Name and Address of Agent For Service) (617) 649-8600 (Telephone Number, Including Area Code, of Agent For Service) Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-acceleratedfiler, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2of the Exchange Act.

| Large accelerated filer |     | ☒ |     | Accelerated filer         |     | ☐ |
| Non-accelerated filer   |     | ☐ |     | Smaller reporting company |     | ☐ |
|                         |     |   |     | Emerging growth company   |     | ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

EXPLANATORY NOTE

This Registration Statement on Form S-8, relating to the 2023 Stock Incentive Plan, as amended, of Agios
Pharmaceuticals, Inc. (the “Registrant”), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has
previously been filed and is effective. Accordingly